Dr. Neelapu on Managing Toxicities Associated with CAR T-Cell Products in Lymphoma

Video

Sattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.

Sattva Neelapu, MD, a professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.

Two acute toxicities that are commonly associated with CAR T-cell therapy include cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), Neelapu, says. CRS typically occurs in patients within the first week of infusion, while ICANS often develops within the second week, Neelapu explains.

Typically, these adverse effects are reversible, Neelapu notes. The key to managing these toxicities is close monitoring, using the appropriate grading system to determine severity, and then treating patients accordingly, Neelapu concludes.

Recent Videos
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
© 2025 MJH Life Sciences

All rights reserved.